A clinical-stage biotechnology company in Immuno-Oncology and Immuno-Inflammation

Focused on developing and partnering therapies to control the immune system for Immuno-Oncology and Immuno-Inflammation.

Our latest press release

Read more


OSE Immunotherapeutics’ Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective


To receive OSE Immunotherapeutics’ latest news